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Notch signaling abnormalities are reported to be involved in the acceleration of 
malignancy in solid tumors and stem cell formation or regeneration in various 
organs. We analyzed specific genes for DNA copy number variations in liver 
cancer cells and investigated whether these factors relate to clinical outcome. 
Chromosome 20p, which includes the ligand for Notch pathways, Jagged1, was 
found to be amplified in several types of hepatoma cells and its mRNA was 
upregulated according to α-fetoprotein gene expression levels. Notch inhibition 
using Jagged1 shRNA and γ-secretase inhibitors produced significant 
suppression of cell growth in α-fetoprotein-producing cells with suppression of 
downstream genes. Using in vivo hepatoma models, the administration of 
γ-secretase inhibitors resulted in reduced tumor sizes and effective Notch 
inhibition with widespread apoptosis and necrosis of viable tumor cells. The 
γ-secretase inhibitors suppressed cell growth of the EpCAM+ fraction in 
hepatoma cells, indicating that Notch inhibitors could suppress the stem cell 
features of liver cancer cells. Even in clinical liver cancer samples, the 
expression of α-fetoprotein and Jagged1 showed significant correlation, and 
amplification of the copy number of Jagged1 was associated with Jagged1 
mRNA expression and poor survival after liver cancer surgical resection. In 
conclusion, amplification of Jagged1 contributed to mRNA expression that 


















Globally, liver cancer has one of the poorest prognoses of all cancers 1. Many 
liver cancer patients experience recurrence after effective treatments, including 
surgical resection at stage I, leading to high mortality rates. The etiologies of 
liver cancer include hepatitis B virus (HBV) and hepatitis C (HCV) infection, any 
other chronic liver injury such as primary biliary cirrhosis or autoimmune hepatitis, 
metabolic diseases such as non-alcoholic steatohepatitis or diabetes, and 
exposure to aflatoxin, a harmful chemical substance. Although the direct 
oncogenic factor of HCV-related liver cancer has not yet been discovered, HBV 
is reported to be associated with oncogenic factors of viral infection, including 
HBV-x genome. Moreover, a recently developed effective antivirus therapy for 
both HCV and HBV, using direct-acting agents in HCV or nucleos(t)ide 
analogues in HBV, has led to some patients developing liver cancer without 
developing advanced liver disease like cirrhosis. However, this oncogenic 
mechanism has not been resolved completely even in HBV and could become a 
major problem in the near future. Serological tests are performed to diagnose 
liver cancer, to determine the appropriate therapies, and to monitor their effects. 
The most important serological tumor markers are α-fetoprotein (AFP) or 
PIVKA-II. AFP is also associated with angiogenesis, and tumor cell growth, 
invasion, and metastasis. From hierarchical expression analysis using 
microarray, ephrin family genes have been found to be linked to AFP elevation or 
angiogenesis 2. Serum AFP elevation or overexpression in the tissue can be 
seen in liver cancer samples; however, other proteins have also been 
discovered. For example, glypican 3 is significantly elevated and EpCAM plays 
an important role in liver cancer progenitor cells 3-5. Recent bioinformatics 
techniques have been applied to find proteins related to abnormal cellular 
signaling in liver cancer samples. We examined gene expression patterns using 
RNA samples of liver cancer tissue, including clinical samples, in addition to 
hepatoma cell lines or hepatoma cells in experimental small animals. At the DNA 
level, genomic alterations such as single nucleotide polymorphisms, loss of 
heterogeneity, or copy number amplifications or deletions were found and these 
resulted in specific changes in liver cancer samples 6, 7. Southern blotting, FISH 
(fluorescence in-situ hybridization), and CGH (comparative genomic 
hybridization) have been used in cytogenetic studies. Recent progress in 
bioinformatics techniques has led to the discovery of specific genomic 
alterations in solid tumors such as tumors of the breast, colon, and pancreas, 
and these have been useful for diagnostics and in the selection of therapy. The 
same techniques have also resulted in the identification of specific genomic 
alterations in liver cancer. Altered genomic patterns in liver cancer influence 
patient mortality. A specific genomic location altered in liver cancer samples was 
reported to be associated with carcinogenesis or mitosis of the tumor cells. 
Previously, we reported that genomic alteration patterns affect the expression 
patterns in hepatoma cell lines and are associated with AFP production 8. 
Referring to related genes on microarray, we could estimate the types of genes 
involved and the candidate cell-cell interaction genes. Since it was important to 
determine whether a specific gene could be involved with a possible molecular 
therapeutic target or one of the pathways in a molecular target in clinical 
samples, we used microarray results to detect genomic abnormalities. 
 
 
Materials and Methods 
Hepatoma and non-hepatoma cell lines 
For genomic and gene expression analysis, we selected seven hepatoma cell 
lines: Huh7, HepG2, Hep3B, Huh6, and PLC/PRF/5, all of which produce AFP, 
and two cell lines, HLE and SKHep1, which do not. Human cervical cancer cell 
line HeLa and bile duct cancer cell line KMBC, neither of which produce AFP, 
were also analyzed as non-hepatoma cells. THLE-5b cells, a normal hepatocyte 
immortalized by using SV40, was selected for normal gene expression control 
for real-time detection polymerase chain reaction (RTD-PCR) gene expression 
analysis 9. 
 
Clinical liver samples (frozen liver cancer samples) 
Genetic analysis of frozen tumor samples from 38 liver cancer patients was 
conducted using RTD-PCR. Most samples were collected during surgery. The 
patients included 17 who had HBV-related liver cancer and 18 who had 
HCV-related liver cancer; the remainder had other etiologies. We observed AFP 
expression in hepatoma tissue samples and it was upregulated in around 37% of 
samples (6 HBV, 6 HCV, 2 non-B and non-C). Surgery was performed on 
patients diagnosed from October 2000 to September 2006 at Kanazawa 
University Hospital. All patients gave informed consent for their tissues to be 
used for genomic analysis. By isolating genomic DNA from eight patients with 
elevated AFP expression (one sample was from an autopsy liver), we observed 
genomic copy number changes using RTD-PCR by comparing the samples with 
non-cancerous tissues. 
 
Clinical liver samples 
Formalin-fixed paraffin-embedded (FFPE) samples from 115 liver cancer 
patients were selected and genomic DNA was isolated by checking the tumor 
area under a microscope using similar H-E stained slices and scraping off tumor 
cells from samples on the glass slide. Genomic DNA isolation was performed 
using Min-elute FFPE kit (Qiagen, Venlo, Netherlands). Surgery had been 
performed in patients diagnosed from 2004 to 2010 who gave consent for the 
genetic analysis of tissues. Of these samples, 31 were HBV-related liver cancer, 
54 were HCV-related, 1 was both HBV and HCV infected, and 29 were non-HBV 
and non-HCV. 
 
BAC array hybridization and comparison with in-house cDNA chip 
Seven hepatoma cell lines and two non-hepatoma cell lines were used for BAC 
microarray CGH. Manufactured microarray slides contained 1440 BAC clones, 
which covered most major chromosome regions (Macrogen, Seoul, South 
Korea). Genomic DNA (0.5 µg) from tumor cells was labeled by Cy5-dUTP (GE 
Healthcare Life Sci., Uppsala, Sweden) and the same amount of control 
genomic DNA from peripheral blood mononuclear cells (PBMCs) of healthy 
volunteers was labeled by Cy3-dUTP (GE) and hybridized onto slides at 37 °C 
overnight. The microarray technique was similar to the conventional method. A 
microarray scanner was used to calculate the intensity of each dye, and we 
analyzed the BAC clone spots in each chromosomal region using MAC ViewerTM 
(Macrogen) and viewed the log ratio chart. We compared the expression profiles 
from the results of the cDNA in-house microarray (Kanazawa chip Ver 2.1, 9600 
spots) and analyzed the same cell line samples 8. These BAC array CGH 
datasets have been deposited in NCBIs Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/); GEO Series accession number GSE77224. 
 
Real-time detection PCR of Notch-related genes 
RTD-PCR was performed using cDNA from clinical samples or cell lines to 
measure the expression of Jagged1 and AFP. We also checked the expression 
levels of other Notch-related genes, Notch1 and HES1. We measured the 
genomic copy number variation (CNV) of Jagged1 using RTD-PCR for genomic 
DNA samples. We used master mix reagent for RTD-PCR (Life Technologies, 
Carlsbad, CA) and performed amplification using ABI7900 (Life Technologies). 
For CNV analysis, we used two different areas of the Jagged1 probe, and CNV 
calculation was performed using CopyCallerTM software (Life Technologies). 
 
Cell growth assay after Jagged1 shRNA silencing 
We measured cell line growth after Jagged1 expression inhibition using shRNA 
vector (MISSION shRNA, Sigma-Aldrich St. Louis, MO). Cell growth for up to 
120 h in Huh7, HepG2, HLE, and SKHep1 cells was compared using Jagged1 
and a non-targeting negative control after infection by these lentivirus 
transfected vectors. After puromycin selection, we compared cell growth using 
Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan).  
 
Notch inhibition by Notch inhibitors (γ-secretase inhibitors) 
To disrupt Notch signaling in hepatoma cells, we used two Notch inhibitors, 
L-685,485 and DAPT ((3,5-Difluorophenylacetyl)-Ala-Phg-OBut) (Peptide 
Institute, Inc., Minou, Japan). These drugs, γ-secretase inhibitors (GSI), are 
administered to prevent amyloid beta accumulation and have been used in 
clinical trials in Alzheimer patients. In addition to Alzheimer’s research, many 
trials are ongoing for solid malignant tumors, such as breast cancers, lung 
cancer, and colorectal cancers 10, 11. L-685,458 strongly inhibits amyloid beta, 
thus it is widely used in basic research, while DAPT has similar inhibitory effects 
but needs a greater concentration to inhibit signal peptide peptidase (SPP) 12, 13. 
We observed cell proliferation in four hepatoma cell lines (Huh7, HepG2, HLE, 
and SKHep1) after administrating 10 μM of these drugs. We measured data from 
five wells for each sample and calculated absorption to measure cellular growth. 
We changed the medium at 24, 48, 72, 96, and 120 h and checked cell growth at 
0, 72, 120, and 168 h (Huh7 and SKHep1), or 0, 48, 96, and 168 h (HepG2 and 
HLE). The reason for varying the measurement times was that cellular growth 
differed depending on cell lines and we could not estimate the confluent state for 
these cell sets. Moreover, we checked the expression of the downstream gene, 
HES1, in Huh7 and HLE by RTD-PCR.  
 
Cell separation of EpCAM+ and EpCAM- Huh7 cells 
Since Huh7 cells include the heterogenic EpCAM+ stem cell feature and this 
stem cell population is associated with the malignant characteristics of cells, we 
separated EpCAM+ and EpCAM- fractions using FACS cell sorter (FACS Aria III, 
BD, Franklin Lakes, NJ). Cells were spread onto culture dishes after sorting and 
incubated at 37 °C in 5% CO2. After several passages, we administrated 10 μM 
of L-685,458 and DAPT. Relative cellular growth rates were analyzed using Cell 
Counting Kit-8. 
 
GSI treatment for NOD-SCID mouse hepatoma models 
Seven-week-old NOD-SCID mice (NOD.CB17-Prkdc<SCID>/J, male) (Charles 
River Laboratories, Wilmington, MA) were given subcutaneous injections of 1 x 
105 of Huh7 cells. Percutaneous administration of 5 mg/kg doses of L-685,458 
and 20 mg/kg doses of DAPT dissolved in DMSO, or DMSO alone (control) was 
started. To compare tumor size, we injected these drugs three times per week, 
sacrificed the mice after 2 weeks, and measured the hepatomas. To assess 
survival, we injected drugs twice a week and observed the mice for up to 6 
weeks after the injections. Thereafter, we sacrificed the remaining live mice, and 
applied immunofluorescence. Several specific polyclonal antibodies were added 
to paraffin-embedded tumor samples before staining with DAB and hematoxylin. 
We calculated the CK19 stained areas in the cells and compared the control and 
GSIs-treated mouse tumor samples using Image J software (NIH). 
 Results 
20p genomic amplification of hepatoma cell lines using array-based CGH 
We analyzed the genomic amplification and deletion of hepatoma cells using 
BAC microarray CGH. Five of the cell types produce AFP (Huh7, Hep3B, Huh6, 
PLC/PRF/5, HepG2) while two do not (SKHep1 and HLE). The genomic DNA of 
these cells was previously analyzed using cDNA microarray CGH, and it was 
found that AFP production is associated with a different genomic cluster of cells 8. 
A similar result was observed in cDNA and BAC array CGH but some results 
were different. This was because the target DNA on the array slide was different 
and exons but not introns were present, in contrast to genomic DNA, thus the 
intron sequence was skipped. Moreover, the length of the cDNA was shorter 
than the BAC clone. The genomic DNA was amplified sequentially in some 
chromosome locations and deleted in others. The 20p position was particularly 
amplified compared with other chromosome locations, although we found other 
genomic alterations at other locations (Figure 1A). Since we have already 
reported that AFP-positive and -negative hepatoma cells can differentiate 
between genomic amplification and expression, we mixed the data of each spot 
from the BAC array and calculated the average AFP-positive and -negative 
characteristics (Figure 1B). The copy number differed at other chromosomal 
locations based on AFP-producing status—these differences were strong, 
especially in the 20p location.  
 
Amplification and overexpression of Jagged1 gene in AFP-positive 
hepatoma cells 
We selected genes in each of the BAC clones to focus on 20p in the BAC 
microarray (Table 1). Although not all spots in the BAC array expressed genes, 
several were found during the analysis. From 9800 in-house genes of cDNA 
microarray, several were located in the 20p area (underlined genes) and we 
compared the average expression ratio in AFP-positive and -negative cell lines 
for some genes. We found that the Jagged1 gene showed a distinct pattern 
(Table 1, Figure 1A). The underlined genes in Table 1 are listed on the in-house 
9800 microarray. The expression of other genes was not upregulated in 
AFP-positive cells. Using cDNA microarray, we previously showed that 
AFP-positive and -negative cells had differential gene expression and genomic 
alterations 5. We focused on the Jagged1 gene and analyzed its role in 
hepatoma cells or clinical samples. Using the RTD-PCR method, Jagged1 
genes showed distinct upregulation in AFP-positive cell lines and 
downregulation in AFP-negative cell lines (Figure 1C). Furthermore, the data 
showed that Jagged1 gene was not upregulated in non-hematoma cell lines 
such as HeLa. We analyzed alterations in the Jagged1 copy number using 
RTD-PCR and found that most of the cell lines showed similar expression, 
except HLE cells (Figure 1D).  
 
Cell growth suppression in AFP-producing hepatoma cells after Jagged1 
shRNA silencing 
Strong suppression of cell growth in Huh7 and HepG2 cell lines was found after 
shRNA silencing of Jagged1 gene (Figure 2). However, AFP-negative cells, HLE 
and SKHep1, showed no growth suppression. We also performed Jagged1 
siRNA knock-down and evaluated cell growth; however, no significant 
suppression was observed, even in Huh7 and HepG2 cells (data not shown). 
RTD-PCR confirmed that downstream HES1 gene expression was suppressed 
in Huh7 for Jagged1 siRNA (Supplement Figure 1). The reason for this result 
may be because the induction of Jagged1 knockdown by siRNA was not efficient 
and successful transfection might only have occurred in a small number of cells.  
 
Effect of Notch signal inhibition of hepatoma cells by γ-secretase 
inhibitors 
Two types of γ-secretase inhibitors, L-685,458 and DAPT, were used for the 
cellular reaction of Notch pathway inhibition among hepatoma cell lines. 
L-685,458 and DAPT diluted with DMSO were added to cells and cell 
proliferation was compared with the control (DMSO alone). Inhibition occurred in 
Huh7 and HepG2, which are AFP-producing cell lines, whereas there was no 
significant inhibition in non-AFP-producing cell lines, HLE and SKHep1 (Figure 
3A). We calculated IC50 values for these cells and the values of L-685,458 
treated groups were smaller than those treated with DAPT and were smaller in 
Huh7 cells than in other cells (Table 2). Notch-related gene expression after 120 
h showed that HES1 expression was suppressed using the two types of GSI in 
both Huh7 and HLE (Figure 3B). However, other Notch signaling-related genes, 
Jagged1, Notch1, and Notch2, were not altered apart from Notch1 expression 
after DAPT treatment in HLE, suggesting that only downstream genes are 
affected by GSIs.  
 Effectiveness of γ-secretase inhibitors in EpCAM+ cancer stem cells 
Notch signaling plays a role in the functions of stem cells and EpCAM+ is 
strongly associated with cancer stem cells in hepatomas. Cell growth was 
compared after GSI treatment in EpCAM+ and EpCAM- Huh7 cell fractions after 
separation using a cell sorter. We observed significant cell growth suppression in 
EpCAM+ cells with DAPT, and L-685,458 suppressed both EpCAM+ and 
EpCAM- features, suggesting that GSI have anti-tumor effects, even in 
hepatoma cells with the EpCAM+ cancer stem cell feature (Figure 3C). 
 
Anti-tumor effect of Notch inhibitors in mouse hepatoma models 
Slower tumor formation was observed after 2-week administration of Notch 
inhibitors, L-685,458 and DAPT (Figure 4A). The effect was more pronounced 
for DAPT (p=0.04) and after a longer period of observation, there was a 
tendency for earlier death in control cases (Figure 4B). The dynamic tumor 
status in GSI cases after longer administration showed tumor necrosis and 
apoptosis (Figure 4C). We found that EpCAM staining was weak in GSIs groups 
except in necrotic areas, suggesting GSIs had inhibited EpCAM production 
(Figure 4C). Moreover, CK19 staining was significantly reduced in GSI cases 
(p<0.001), which indicated that the malignant characteristics of the hepatoma 
cells were controlled (Figure 4D). Brighter hematoxylin staining in GSI-treated 
cases indicated that HES1 staining was diminished in the nucleus (Figure 4C). 
Jagged1 and Notch1 were stained by immunofluorescence in control tumor 
samples; however, these stains were not changed in the L-685,458 or DAPT 
treatment groups. This result showed that ligands and receptors were not 
affected by γ-secretase inhibitors (Supplement Figure 2A). This is reasonable 
data; we checked RTD-PCR data of HES1 and found a decrease after 
γ-secretase inhibitor treatment (Supplement Figure 2B).  
 
Association between amplification of Jagged1 genome in liver cancer 
tissues and poor prognosis 
Genomic DNA in FFPE samples from surgically resected liver cancer cases was 
analyzed and the cases were followed for up to 5 years after surgery. High 
Jagged1 CNV cases (≥1.5 fold) and low CNV cases (<1.5 fold) were divided and 
the clinical characteristics compared. Advanced TMN classification and positive 
vascular invasion were associated with high Jagged1 CNV (Table 3). 
Multivariate analysis showed that high Jagged1 CNV (≥1.5 fold) in cases of liver 
cancer recurrence after surgical resection was associated with survival (Table 4). 
Copy number alterations were analyzed using two different areas of the Jagged1 
genome locus and the proximal copy number multiple of 0.5 was calculated. 
CNV analysis of the Jagged1 locus in 110 liver cancer samples revealed that 
high CNV cases (≥1.5 fold, 65 cases) had significantly lower survival rates 
(p=0.019) compared with low CNV cases (<1.5 fold, 45 cases) (Figure 5A). We 
also classified three groups (CNV≥2.0-fold, 28 cases; 2.0≥CNV>1.5, 37 cases; 
CNV<1.5-fold, 45 cases), and higher CNV groups showed poorer survival rates 
compared with lower CNV cases (p=0.014) (Figure 5B). AFP elevation status 
was analyzed since Jagged1 amplification is observed especially in 
AFP-producing hepatoma cells in vitro. We classified the two groups according 
to the presence (≥100 ng/mL) or absence of AFP elevation. There was 
significantly higher Jagged1 CNV in AFP-elevated cases (Figure 5C). 
The expression of AFP and Jagged1 genes among frozen resected liver cancer 
tissues were compared using RTD-PCR. AFP and Jagged1 expression showed 
significant correlation after the selection of AFP-upregulated samples (p<0.05). 
Moreover, there was a strong correlation between AFP expression and Jagged1 
genome amplification (p<0.01) (Figure 5D, 5E). Jagged1 expression and 
Jagged1 genome amplification also correlated (p<0.05) (Fig. 5F), suggesting 
that the AFP value was associated with Jagged1 expression and genome 
amplification in clinical samples. We also confirmed a correlation between 
Jagged1 and Notch1 expression by RTD-PCR using these samples. We 
assessed Notch1 and downstream HES1 genes and found a strong correlation, 
which suggested that Notch signaling was upregulated in AFP-positive clinical 
tissues (Supplement Figure 3AB).  
 
Discussion 
Genomic alterations such as genome copy number gain or loss in cancerous 
cells can be analyzed using microarray based CGH 6, 14. Amplified or deleted 
regions are found in various types of cancers but these specific abnormal 
regions differ in different organs 15. Some reports show that regions of genomic 
alterations in cancer are associated with expression abnormalities 16, 17. We 
previously reported a significant association between altered genomic copy 
number and gene expression patterns in hepatoma cells, and using hierarchical 
clustering analysis by microarray found that the factor involved was 
AFP-producing status 8. Chromosome 20p locations in hepatoma cells 
apparently differed in terms of genomic copy number, and AFP-producing 
hepatoma cells differed from non-AFP-producing cells. A previous report showed 
genomic alterations in liver cancer using CGH analyses and frequent gains were 
observed in 1q, 6p, 8q, and 17q, whereas losses were observed in 4q, 8p, 13q, 
16q, and 17p. In addition to these gained locations, 20p11 was also present in 
some liver cancer tissue 18. Moreover, five BAC clones for this experiment were 
found listed in BAC array CGH, but only Jagged1 gene was a candidate 
because the different expression patterns were associated with the 
AFP-producing status of hepatoma cells using microarray. 
Notch signaling pathway is widespread and essential for cell-cell interactions or 
intracellular transduction by Notch intracellular domain (NICD) 19. Notch ligands 
and receptors perform major roles in this pathway and abnormalities such as 
point mutations are reported to be the cause of Alagille syndrome, a systemic 
disorder in humans 20, 21. In the oncology field, Notch signaling abnormalities are 
related to carcinogenesis or tumor vessel abnormalities 22, 23. Notch 
signaling-targeted therapy has been developed in the field of neural diseases 
such as Alzheimer’s disease. One of the Notch inhibitors, γ-secretase inhibitor, 
restricts cleavage of the Notch receptor in the cell membrane and disturbs signal 
transduction by NICD. Clinical trials were underway but reports of 
gastrointestinal toxicity halted further study 24. This drug is useful for inhibiting 
aggregation of amyloid protein in Alzheimer’s disease 25, while its effectiveness 
has been reported in the oncology field in targeted molecular therapy 26. For 
example, hematopoietic tumor therapy is highly effective and various clinical 
studies in other solid tumors are ongoing 27-29.  
Some genomic alteration studies have already been performed in liver cancer 
samples and many reports using array CGH method or other new bioinformatics 
techniques have been published 30. Genome amplification of cancer cells usually 
shows that the check point system for DNA repair was destroyed leading to gene 
amplification, especially in malignant cells, including those of liver cancer. 
However, it is important to consider that liver cancer includes several histological 
types and genomic alteration patterns differ by type; variations occur in 
differentiation, stem cell features, AFP production, and so forth. The etiologies 
also differ since advanced chronic liver injury can be caused by HBV, HCV, or 
other factors. Some reports suggest that genomic abnormalities in liver cancer 
cause poor survival and candidate genes have been reported; however, they are 
not associated with the development of any clinical drugs 31. Our method  
selected genes by microarray analysis but we concluded that these candidate 
genes would be important for future effective liver cancer therapy. The 
relationship between genomic and expression alterations can explain their 
oncological significance. We investigated the importance of AFP-producing 
status in hepatoma cells using genome microarray analysis of expression. We 
focused on Jagged1 gene because it was both amplified and overexpressed in 
AFP-positive hepatoma cells. In another report, Jagged1 expression was 
associated with HBV-x genes 32; however, we included HCV-infected clinical liver 
cancer cells. Mutations in Jagged1 gene are reported to cause abnormalities of 
the bile duct cells and Alagille syndrome in the gastroenterology field. However, 
an association with cancer has not been investigated. By conducting 
Notch-related basic research, Notch ligand and receptor expression 
abnormalities have been linked to several types of cancers. Jagged1 gene 
expression abnormalities in liver cancer have already been reported, although 
copy number changes have not been discussed 33. Yet, recent cancer research 
has revealed that copy number changes in specific genes are associated with 
carcinogenesis or the aggressiveness of the cancer and correlate with patient 
survival 34, 35. In the hepatological field, some reports have mentioned links 
between genomic alterations, severity of liver cancer, and survival 36, 37. Our 
study revealed a correlation between AFP elevation and Jagged1 genomic copy 
number changes. Based on array CGH data and PCR-based CNV assay, 
Jagged1 CNV was not reduced in HLE cells even though these are not 
AFP-producing cells. This means Notch signaling, including Jagged1 
underexpression, is applicable to non-AFP producing cells, but the decrease in 
Jagged1 CNV does not fully correlate in these cells. This data indicated that HLE 
cells are an exception but Notch transduction suppression was significant. 
Furthermore, the data showed that CNV value was not elevated, which indicated 
that Jagged1 CNV did not change in these cells and underexpression of 
Jagged1 was not directly associated with a decrease in Jagged1 CNV. We 
analyzed the genomic alterations of Jagged1 genes and AFP elevation using 
surgically resected samples. AFP elevation and overexpression of Jagged1 
gene were calculated and related to liver cancer cases with elevated AFP. Using 
surgical samples, RTD-PCR showed that AFP expression and Jagged1 genomic 
copy number changes also correlated. We concluded that the genomic copy 
numbers of Jagged1 gene were associated with AFP expression. Notch-related 
gene expression analysis after Jagged1 knockdown indicated that Notch signal 
transduction affected HES1 gene by modulation of the Notch ligand.  
In hepatoma cells, γ-secretase inhibitors can be used both in vitro and in vivo. 
The results showed that, compared with the control, these drugs significantly 
inhibited growth in AFP-producing hepatoma cells. However, growth was 
strongly inhibited using DAPT but not L-685,458 in KMBC cell lines (data not 
shown). This result suggested that any bile duct cell-related cause could be 
efficiently suppressed by the administration of Notch inhibitors. We used two 
types of Notch inhibitor L-685,458 and DAPT. The former is a more efficient SPP 
(signal peptide peptidase) inhibitor than DAPT, and SPP is essential for HCV 
replication 12. This inhibitor does not directly inhibit Jagged1 because it is a 
ligand in the cells and in cell interactions, but from our results, there appears to 
be some association, which will be investigated in further in vivo experiments. 
Recent clinical oncology research showed that the chemical was more effective 
in combination with currently used drugs, such as sorafenib, for advanced 
stages of liver cancer than as a monotherapy 38-40. It may provide effective data 
for in vitro or in vivo models. Since Notch signaling exists even in 
non-AFP-producing cells, it can suppress downstream HES1 genes via GSI in, 
for example, HLE cells. Since GSI catalyzes the membrane protein that affects 
Notch1 cleavage, it may not reduce Jagged1, Notch2, or even Notch1. Hence, 
our data implies that the expression of upstream Jagged1 expression and other 
receptors are not affected. Furthermore, the reason why Notch1 was 
significantly suppressed by DAPT only in HLE might be because it was 
suppressed in both Huh7 and HLE cells, and showed Notch1 consumption by 
not restricting Jagged1-Notch1 signaling, especially in HLE. We demonstrated 
an anti-tumor effect in AFP-producing hepatoma cells and that GSI caused cell 
growth suppression even in EpCAM+ Huh7 cells. This data suggests that GSIs 
could be aimed towards the more malignant features of cells as promising new 
targeted molecular therapy. Liver progenitor cells and cancer stem cells are 
sensitive to GSI treatment based on our experiments. Previous studies show 
that hepatoma cell lines and liver cancer tissues are heterogeneous and cancer 
stem cells expressing EpCAM can be separated 3, 41. Our experiments showed 
that anti-tumor effects occurred in the EpCAM-positive fraction in vitro, although 
it is difficult to observe precise reactions in clinical tissues. DAPT administration 
resulted in anti-tumor effects only in the EpCAM-positive cell fraction. Since 
these cells are particularly malignant, we would expect good prognoses 
following GSI administration. 
We used NOD-SCID mouse models implanted with human hepatoma cells and 
performed GSI treatment. Tumor formation was suppressed and survival was 
extended by treatment, which indicates that in vivo Notch suppression causes 
effective anti-tumor effects in hepatomas. Although metastasis was not observed, 
earlier death due to tumor enlargement and more dominant viable tumor cells 
occurred in control cases. GSI was dissolved in DMSO, which was also used in 
control cases. Although DMSO shows cytotoxicity in animal models, the amount 
(50 μL/animal) used in this study did not affect survival rates 42. 
Jagged1 CNV analysis of surgically resected liver cancer patients showed that 
amplification was associated with poor survival, and copy number gain resulted 
in poor prognosis. Genomic copy number alterations are associated with survival 
and this result indicated that these changes were associated with malignant 
characteristics and influenced patient survival. This region may exist in other 
regions of the liver cancer genome. Statistical analysis showed that high AFP 
levels are associated with high Jagged1 CNV. Moreover, we found significantly 
shorter OS in higher Jagged1 CNV cases that were dependent on CNV values. 
A comparison of CNV ≥1.5 and <1.5 groups, showed that AFP values were 
unchanged; even if CNV was high at surgical resection AFP is not since it is an 
earlier stage. However, even if AFP is not elevated and Jagged1 CNV is high, 
the clinical course is worse, earlier recurrences of liver cancer occur and AFP 
rapidly increases at the end stage. However, when AFP is high at surgical 
resection, many cases show high Jagged1 CNV; conversely when AFP is low, 
although some patients have higher CNV, in many cases it is lower and the 
clinical course is quite good (Figure 5C). 
We explained that Jagged1 genomic amplification and overexpression is related 
to Notch signal enhancement and AFP positivity and the malignant 
characteristics of liver cancer cells were related to these abnormalities. Though 
the mechanism of AFP production and Notch enhancement were not directly 
explained, Notch signal transduction was associated with the activation of 
cancer stem cells, including those in liver cancer, and we found that the 
EpCAM-positive fraction in hepatoma cells are sensitive to Notch signal 
inhibition. Advanced and end-stage liver cancer clinical cases show much higher 
AFP levels and most show Notch activation including Jagged1 and Notch1 
overexpression. Notch pathways are related to angiogenesis, and 
AFP-upregulated cases show higher levels of angiogenic factors, such as the 
Ephrin family reported previously by our group, thus it is reasonable to expect 
Notch signaling activation in AFP-upregulated cases2. Epidemiological studies 
show that liver cancer has a poor prognosis; therefore, it is important to focus on 
molecules that are well-known liver tumor markers, such as AFP.  
Our results showed that the Jagged1 genomic region and Notch activity are 
associated with the malignant characteristics of liver cancer and can predict the 
outcome of liver cancer therapy. 
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In vitro genomic copy number and expression analysis in hepatoma or 
non-hepatoma cells. (A) Genomic copy number changes of chromosome 20 in 
each cell line using BAC microarray. Copy number changes in each 
chromosome area were calculated using commercial software (MAC viewer, 
Macrogen Inc., South Korea). Human hepatoma cell lines (Huh7, HepG2, Huh6, 
Hep3B, PLC/PRF/5, HLE, and SKHep1) and human non-hepatoma cell lines 
(KMBC and HeLa) were analyzed by comparing with healthy human volunteer 
PBMCs as control. Red dotted lines with arrows indicate Jagged1 gene copy 
number changes in 20p12.2. Values above zero show copy number gains and 
those below indicate copy number losses. Average log2 (Cy3/Cy5) signal ratios 
of BAC clones were calculated for each sample and a threshold of 0.25 log2 
ratio units was used for defining copy number gains and losses. (B) Mean copy 
number changes between hepatoma (yellow) and non-hepatoma (green) cell 
lines and AFP positive (yellow) and negative cells (green). (C) RTD-PCR 
analysis of Jagged1 gene in cell lines. These values are log based 
Jagged1/β-actin expression ratios. Huh7, Hep3B, HepG2, PLC/PRF/5, and 
Huh6 cells are AFP-producing, whereas SKHep1, HLE and HeLa are not. (D) 
RTD-PCR analysis of Jagged1 genome in cell lines. These values were 
calculated by comparing changes with genomic changes in healthy PBMC. 
 Figure 2 
Jagged1 inhibition of hepatoma cells impacts on tumor growth in vitro. Cell 
growth after Jagged1 shRNA transfection in Huh7, HepG2, HLE, and SKHep1 
cells. Huh7 and HepG2 are AFP-producing cells and HLE and SKHep1 are 
non-producing cells. In Jagged1 shRNA transfected cells (black), cellular growth 
was compared with control shRNA transfected cells (red). *** P<0.001. 
 
Figure 3 
Notch inhibitor impact on AFP-producing and EpCAM+ hepatoma cells in vitro. 
(A) Relative cellular growth curve of hepatoma cell lines after administration of 
γ-secretase inhibitors L-685,458 and DAPT. We administered 10 µM of each 
reagent dissolved in DMSO at 0 h, 72 h, 120 h, and 168 h and blank reagents 
that included only DMSO (control). *** P<0.001; Control versus L-685,458 and 
DAPT. (B) Relative expression of HES1, Jagged1, Notch1, and Notch2 after 
L-685,458 and DAPT treatment in Huh7 and HLE cells. Total RNA was isolated 
after 120 h administration. *** P<0.001. (C) Relative cellular growth of L-685,458 
or DAPT-treated Huh7 cells after separation of EpCAM+ and EpCAM- fractions 
using FACS. We compared 120 h of cellular growth in each with the DMSO 
control. * P<0.05. 
 
Figure 4 
Anti-tumor effect of γ-secretase inhibitors in NOD-SCID mouse models 
implanted with Huh7 cells.  (A) Tumor size comparison between L-685,458, 
DAPT, and negative control after 2 weeks of treatment. Tumor diameters of each 
of the five tumor samples were analyzed. * P<0.05. (B) Cumulative survival rate 
compared between GSI (L-685,458 and DAPT) and control cases. Survival rates 
of each of the five samples were compared and calculated using the log-rank t 
test. ** P<0.01. (C) Immunostaining using anti-caspase 3, CK19, HES1 and 
EpCAM antibodies for control and L-685,458-treated tissues. Immunostaining 
was performed using DAB, and cellular nuclei were stained by hematoxylin. 
Scale bars = 100µm. (D) Quantification of CK19-positive cells between control 
and GSIs. Calculations were performed for each of five CK19 immunostained 
slides. *** P<0.001. 
 
Figure 5 
Amplified Jagged1 liver cancer patients have poor survival. We analyzed 
Jagged1 CNV in liver cancer tissue in FFPE and frozen tissue to compare 
genomic alterations and expression using RTD-PCR. (A) Overall survival data 
after surgical resection of liver cancer was divided into two groups (CNV<1.5 
and ≥1.5 (CNV: copy number variations)). The p-value was calculated using 
log-rank t test. We followed patients for up to 60 months after surgery. * P<0.05. 
(B) Overall survival data divided into three groups (CNV<1.5, CNV=1.5 and 
CNV≥2). * P<0.05. (C) Comparison of CNV values in two groups of high (≥100 
ng/mL) and low (<100 ng/mL) AFP using the Mann-Whitney U test. We used the 
day of surgery as the approximate date that the serum AFP values were 
obtained. ** P<0.01. (D) Relationship between Jagged1 and AFP expression by 
RTD-PCR using frozen liver cancer tissues. We analyzed only AFP upregulated 
liver cancer tissues. (E) Relationship between Jagged1 genomic alterations and 
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ratio of AFP+ cells 
/AFP- cells 
BAC40_E05 20p13 110124 LOC343637, RSPO4   
BAC109_E03 20p13 97397 ATRN, GFRA4, ADAM33 NM_139321 0.88 
BAC127_K22 20p12.3 91214 C20orf30, PCNA, CDS2 NM_002592 0.98 
BAC85_D15 20p12.3 100000    
BAC155_K05 20p12.3 90398 PLCB1   
BAC143_E21 20p12.2 98802 PLCB4 NM_000933 1.08 
BAC86_O12 20p12.2 136522 JAG1 NM_000214 2.14 
BAC165_M10 20p12.1 88468    
BAC86_O11 20p12.1 153399 MACROD2, CR596518   
BAC81_M07 20p12.1 126920 MACROD2   
BAC81_K08 20p12.1 88837 KIF16B   
BAC29_A11 20p12.1 131740 RPL7AL3, SNRPB2, OTOR NM_003092 0.4 
BAC132_A05 20p12.1 93613    
BAC96_K10 20p12.1 112559 PCSK2, BFSP1 NM_002594 0.99 
    
NM_001195 0.98 
BAC44_G02 20p11.23 110517 DTD1   
BAC75_H16 20p11.23 108696 KIAA1272, RALGA1A2 C20orf74,    
   AK026194   
BAC63_I12 20p11.22 104597 NKX2-2   
BAC110_E03 20p11.21 113928 VSX1, ACSS1   
BAC36_M13 20p11.21 173706 ENTPD6, PYGB, C20orf22,  NM_001247 
 
1.6 
    PPIAP2, BC128043, ABHD12, NM_002862 0.79 
   CD39L2   
BAC204_A05 20q11.21 89320 CBFA2T2   
BAC140_D09 20q11.23 125023   
BAC43_F22 20q12 171393 LOC339568   
BAC239_E02 20q12 91366 CR612573, CR593014   
BAC97_K09 20q12 76966 LPIN3, EMILIN3, KIAA1335, CH06   
BAC21_G16 20q12 109908    
BAC52_H17 20q12 114526 PTPRT NM_133170 0.87 
BAC75_I24 20q13.12 86258 ADA, AK090842, CR597563  NM_000022 0.71 







STAU1   
BAC193_H13 20q13.13 102377    
BAC72_N10 20q13.2 95499  
BAC51_F06 20q13.2 224038    
BAC97_O05 20q13.2 102916    
BAC63_G09 20q13.32 121623 PPP4R1L, RAB22A   
BAC142_K22 20q13.32 81986 PHACTR3, SYCP2   
BAC42_C03 20q13.33 102953 CDH4, AK097866 NM_001794 1.11 
 Underlined representative genes; 9800 in-house cDNA microarray listed genes. 




 L-685,458 DAPT 
Huh7 12.91±0.55 118.26±40.42 
HepG2 12.69±4.60 155.27±7.58 
HLE 21.76±0.84 244.86±7.95 
SKHep1 12.18±2.90 153.24±14.38 
 
Table 3 Clinical characteristics of liver cancer patients who had undergone surgical 
resection 
 
Clinical category CNV ≥ 1.5 CNV < 1.5 p-value 
No. of patients n = 68 n = 47 
 
Sex (M vs. F) 50 vs. 18 39 vs. 8 0.234 
Age (years) 63 (38-82) 66 (44-80) 0.054 
Viruses (HBV / HCV / non-B non-C) 21 / 33 /15a 11 / 22 / 14 0.540 
Child Pugh score (5 / 6 / ≥7) 55 / 5 / 6b 36 / 7 / 1c 0.054 
AFP (≥100 ng/mL vs. <100) 27 / 41 11 / 36 0.067 
PIVKA-II (≥100 mAU/mL vs. <100) 35 / 31 26 / 19 0.622 
Histological grading (mod.-poor. vs. well-mod.) 57 / 11 37 / 7 0.970 
Tumor size (mm) 45 (7-230) 35 (10-150) 0.359 
Tumor morphology (multi vs. uni) 26 / 42 13 / 34 0.239 
Vascular invasion (+ vs. -) 15 vs. 53 1 vs. 46 0.002** 
Liver cancer recurrence (+ vs. -) 31 vs. 26 32 vs. 12 0.059 
a One patient had a double infection of HBV and HCV. 
b The score for two patients could not be calculated. 
c The score for three patients could not be calculated. 
** P<0.01. 
Table 4 Cox regression analysis of clinical and genomic variables associated with 
survival in liver cancer 
 
Variable Univariate Multivariate                               
 
  
  p-value p-value HR     (95% CI) 
Sex (M vs. F) 0.824 0.104 2.639 (0.820 - 8.497) 
Age (≥60 y.o. vs. <60 y.o.) 0.551 0.612 1.258 (0.519 - 3.050) 
Jagged1 CNV (≥1.5 vs. <1.5) 0.002** 0.018* 3.494 (1.243 - 9.816) 
AFP (≥100 vs. <100) 0.079 0.187 1.897 (0.733 - 4.909) 
PIVKAII (≥100 vs. <100) 0.001** 0.930  0.956 (0.353 - 2.591) 
Liver cancer recurrence (Yes vs. No) 0.139 0.001** 9.032 (2.472 - 33.00) 
Child-Pugh scores (≥7 vs. <7) 0.024* 0.113  2.704 (0.789 - 9.268) 
Histological grading                              
(mod.-poor. vs. well-mod.) 
0.221 0.371 2.000 (0.438 - 9.146) 
Tumor size ( ≥30 mm vs <30 mm ) 0.003** 0.060  3.073 (0.954 - 9.899) 
Vascular invasion (+ vs -) 0.001** 0.553 1.423 (0.443 - 4.574) 
* P<0.05 ** P<0.01 
